[IV期结直肠癌患者血清中血管内皮生长因子水平的临床意义]
[Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV].
作者信息
Huang Na, Yang Lin, Cao Meng-ran, Su Ning, Chen Jin-zhang, Lü Cheng-wei, Liao Wang-jun, Luo Rong-cheng
机构信息
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
出版信息
Nan Fang Yi Ke Da Xue Xue Bao. 2009 Feb;29(2):278-9.
OBJECTIVE
To investigate the clinical significance of vascular endothelial growth factor (VEGF) levels in serums of colorectal cancer patients at stage IV.
METHODS
Using enzyme linked immunosorbent assay (ELISA) to detect the VEGF levels in serums of 45 colorectal cancer patients at stage IV, and 20 healthy served as normal control.
RESULTS
The mean concentration of VEGF in 45 colorectal cancer patients at the 7 day after operation were significantly lower than that before operation (P<0.01). The mean concentration of VEGF in the patients who benefit from bevacizumab showed no statistical difference from the levels of who did not benefit (P=0.554).
CONCLUSION
The VEGF levels in colorectal patients at stage IV are lowed as the load of tumor decrease. The circulating levels of VEGF seem not predict the response to bevacizumab in colorectal cancer patients at stage IV.
目的
探讨血管内皮生长因子（VEGF）水平在IV期结直肠癌患者血清中的临床意义。
方法
采用酶联免疫吸附测定法（ELISA）检测45例IV期结直肠癌患者血清中的VEGF水平，并以20例健康者作为正常对照。
结果
45例结直肠癌患者术后7天VEGF的平均浓度显著低于术前（P<0.01）。从贝伐单抗治疗中获益的患者VEGF平均浓度与未获益患者的水平相比无统计学差异（P=0.554）。
结论
IV期结直肠癌患者的VEGF水平随肿瘤负荷降低而降低。VEGF的循环水平似乎无法预测IV期结直肠癌患者对贝伐单抗的反应。
Zotero 插件